Nanoparticle-mediated in vitro delivery of E4orf1 to preadipocytes is a clinically relevant delivery system to improve glucose uptake (original) (raw)

• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88.
  Article Google Scholar
• Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10.
  Article CAS Google Scholar
• WHO. World Health Organization obesity and overweight fact sheet. WHO; 2016. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
• Na H-N, Hegde V, Dubuisson O, Dhurandhar NV. E4orf1 enhances glucose uptake independent of proximal insulin signaling. PLoS ONE. 2016;11:e0161275.
  Article Google Scholar
• Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98:2133–223.
  Article CAS Google Scholar
• Dhurandhar NV. Insulin sparing action of adenovirus 36 and its E4orf1 protein. J Diabetes Complicat. 2013;27:191–9.
  Article Google Scholar
• Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes. 2006;55:2392–7.
  Article CAS Google Scholar
• Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proenca C, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet. 2009;41:1110–5.
  Article CAS Google Scholar
• Kovacs P, Hanson RL, Lee YH, Yang X, Kobes S, Permana PA, et al. The role of insulin receptor substrate-1 gene (IRS1) in type 2 diabetes in Pima Indians. Diabetes. 2003;52:3005–9.
  Article CAS Google Scholar
• Danielsson A, Ost A, Lystedt E, Kjolhede P, Gustavsson J, Nystrom FH, et al. Insulin resistance in human adipocytes occurs downstream of IRS1 after surgical cell isolation but at the level of phosphorylation of IRS1 in type 2 diabetes. FEBS J. 2005;272:141–51.
  Article CAS Google Scholar
• Dhurandhar EJ, Krishnapuram R, Hegde V, Dubuisson O, Tao R, Dong XC, et al. E4orf1 improves lipid and glucose metabolism in hepatocytes: a template to improve steatosis & hyperglycemia. PLoS ONE. 2012;7:e47813.
  Article CAS Google Scholar
• Dhurandhar EJ, Dubuisson O, Mashtalir N, Krishnapuram R, Hegde V, Dhurandhar NV. E4orf1: a novel ligand that improves glucose disposal in cell culture. PLoS ONE. 2011;6:e23394.
  Article CAS Google Scholar
• Shastri AA, Hegde V, Peddibhotla S, Feizy Z, Dhurandhar NV. E4orf1: a protein for enhancing glucose uptake despite impaired proximal insulin signaling. PLoS ONE. 2018;13:e0208427.
  Article Google Scholar
• Hegde V, Na HN, Dubuisson O, Burke SJ, Collier JJ, Burk D, et al. An adenovirus-derived protein: a novel candidate for anti-diabetic drug development. Biochimie. 2016;121:140–50.
  Article CAS Google Scholar
• McMurphy TB, Huang W, Xiao R, Liu X, Dhurandhar NV, Cao L. Hepatic expression of adenovirus 36 E4ORF1 improves glycemic control and promotes glucose metabolism through AKT activation. Diabetes. 2017;66:358–71.
  Article CAS Google Scholar
• Kusminski CM, Gallardo-Montejano VI, Wang ZV, Hegde V, Bickel PE, Dhurandhar NV, et al. E4orf1 induction in adipose tissue promotes insulin-independent signaling in the adipocyte. Mol Metab. 2015;4:653–64.
  Article CAS Google Scholar
• Yoon I, Park S, Kim R, Ko H, Nam J. Insulin-sparing and fungible effects of E4orf1 combined with an adipocyte-targeting sequence in mouse models of type 1 and type 2 diabetes. Int J Obes. 2017;41:1601.
  Article CAS Google Scholar
• Zhang H, Zhai Y, Wang J, Zhai G. New progress and prospects: the application of nanogel in drug delivery. Mater Sci Eng C Mater Biolog Appl. 2016;60:560–8.
  Article CAS Google Scholar
• Na K, Park K-H, Kim SW, Bae YH. Self-assembled hydrogel nanoparticles from curdlan derivatives: characterization, anti-cancer drug release and interaction with a hepatoma cell line (HepG2). J Controlled Release. 2000;69:225–36.
  Article CAS Google Scholar
• Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30:592–9.
  Article CAS Google Scholar
• Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv. 2011;2011:727241.
  Article Google Scholar
• Clogston JD, Patri AK. Zeta potential measurement. In: Characterization of nanoparticles intended for drug delivery. Springer; 2011. p. 63–70.
• Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10:57.
  Article Google Scholar
• Zu Y, Overby H, Ren G, Fan Z, Zhao L, Wang S. Resveratrol liposomes and lipid nanocarriers: comparison of characteristics and inducing browning of white adipocytes. Colloids Surf B: Biointerf. 2018;164:414–23.
  Article CAS Google Scholar
• Yu M, Wu J, Shi J, Farokhzad OC. Nanotechnology for protein delivery: overview and perspectives. J Controlled Rel. 2016;240:24–37.
  Article CAS Google Scholar
• Zhang J, Nie S, Martinez-Zaguilan R, Sennoune SR, Wang S. Formulation, characteristics and antiatherogenic bioactivities of CD36-targeted epigallocatechin gallate (EGCG)-loaded nanoparticles. J Nutr Biochem. 2016;30:14–23.
  Article CAS Google Scholar
• Lee KY, Yuk SH. Polymeric protein delivery systems. Progr Polymer Sci. 2007;32:669–97.
  Article CAS Google Scholar
• Chang H-I, Yeh M-K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed. 2012;7:49.
  CAS Google Scholar
• Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci. 2002;6:319–27.
  Article CAS Google Scholar
• Lian T, Ho RJ. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001;90:667–80.
  Article CAS Google Scholar
• Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007;4:297–305.
  Article CAS Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9:12.
  Article Google Scholar
• Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, et al. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm. 2004;270:93–107.
  Article CAS Google Scholar
• Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 1). Trop J Pharm Res. 2013;12:255–64.
  Google Scholar
• Knudsen KB, Northeved H, Ek PK, Permin A, Gjetting T, Andresen TL, et al. In vivo toxicity of cationic micelles and liposomes. Nanomed Nanotechnol Biol Med. 2015;11:467–77.
  Article CAS Google Scholar
• Hillaireau H, Couvreur P. Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci. 2009;66:2873–96.
  Article CAS Google Scholar
• Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immun. 1999;17:593–623.
  Article CAS Google Scholar
• Krishnapuram R, Dhurandhar EJ, Dubuisson O, Hegde V, Dhurandhar NV. Doxycycline-regulated 3T3-L1 preadipocyte cell line with inducible, stable expression of adenoviral E4orf1 gene: a cell model to study insulin-independent glucose disposal. PLoS ONE. 2013;8:e60651.
  Article CAS Google Scholar
• Shastri A, Peddibhotla S, Feizy Z, Hegde V, Dhurandhar NV. E4orf1 protein requires the distal but not proximal insulin signaling to enhance Glut4 translocation. FASEB J. 2017;31(Suppl 1):31.2–.2.
  Google Scholar
• Na H-N, Dubuisson O, Hegde V, Nam J-H, Dhurandhar NV. Human adenovirus Ad36 and its E4orf1 gene enhance cellular glucose uptake even in the presence of inflammatory cytokines. Biochimie. 2016;124:3–10.
  Article CAS Google Scholar